Histocell will develop a cell therapy against lung fibrosis based on a patent from the CSIC and the Hospital Clínic

Histocell, Hospital Clínic de Barcelona and the Higher Council for Scientific Research (CSIC) have signed a licensing agreement

Dr. Antoni Xaubet i Dra. Ana Serrano amb part del seu equip Histocell, Hospital Clínic de Barcelona and the Higher Council for Scientific Research (CSIC) have signed a licensing agreement by which the Basque biotech will invest a minimum of three million Euros and its industrial capacity for the next three years to move forward the development of drugs against idiopathic pulmonary fibrosis. Genoma España, through Innocash program, will provide 450,000 additional Euros to the company through a financing loan. The team that develops the therapeutic approach that could become the first treatment for idiopathic pulmonary fibrosis is headed by Dr. Ana Serrano, IIBB-CSIC researcher, and Dr. Antoni Xaubet, medical researcher at the Hospital Clínic - IDIBAPS.

Information via Biocat.